Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 16/20 | 0.49 |
| ▸ | MMP1 | P03956 | 16/20 | 0.49 |
| ▸ | MMP3 | P08254 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 8/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068813 | 1.00 | ADAM17 (0.49) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6240560 | 1.00 | ADAM17 (0.49) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6234233 | 0.90 | ADAM17 (0.58) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6237732 | 0.88 | MMP1 (0.54) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL7765006 | 0.88 | MMP1 (0.54) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6236919 | 0.88 | MMP1 (0.54) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6241314 | 0.88 | MMP1 (0.54) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6240863 | 0.85 | ADAM17 (0.54) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6239527 | 0.85 | ADAM17 (0.46) | ADAM17MMP1MMP3MMP9MMP13 | |
| SCHEMBL6237935 | 0.84 | MMP1 (0.52) | ADAM17MMP1MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | ADAMTS5, ADAMTS1, MMP2 | ADAM17 22/4885MMP1 18/4885MMP3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.